BIOVIE INC.
No SEC Form 4 filings for $BIVI in the last 30 days.
See all $BIVI insider activity →BioVie Inc (BIVI) will present Phase 2 trial data for its drug bezisterim at a US government-backed Long COVID workshop. The ADDRESS-LC study showed improvements in fatigue, post-exertional malaise, and cognitive function in severe cases. The trial, funded by a $13.13M grant, enrolled 200 adults with Long COVID. BioVie aims to identify patient subgroups for future Phase 3 trials.
SpaceX committed to a $40B lease for Nvidia chips. Xencor shares rose 20% on positive drug trial results. Surgery Partners surged 46% after a $5.7B acquisition deal. Tesla gained 6% following a Barclays upgrade. Verizon raised 2026 guidance after strong customer additions. Anthropic filed for IPO, with concerns raised about its valuation and spending. FTSE 100 gained 0.7%. Big Tech earnings and Fed decision are key focuses this week.
New to The Street Show #777 features executives from Stewards Investment Capital, BioVie (NASDAQ:BIVI), FreeCast (NASDAQ:CAST), and American Fusion (OTCQB:AMFN). BioVie reports positive long COVID and Parkinson's trial results. FreeCast discusses its media monetization technology. American Fusion presents its fusion power technology. The show airs on Bloomberg Television and YouTube.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning BIVI (BIOVIE INC.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent BIVI coverage spans financial news, technology and ipo.
Conference/workshop presentation tees up incremental clinical readout that could shift expectations for a future Phase 3 confirmatory trial.
Upcoming data release creates speculative interest.
Positive early‑stage data may lift BioVie as investors anticipate a Phase 3 trial.
Positive Phase 2 results may boost investor confidence and drive short‑term price appreciation.
Positive subgroup results may boost investor sentiment.
AlphAI scores every news story that mentions BIVI with an AI model for sentiment and relevance, and aggregates insider trades from BIOVIE INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BioVie Inc (BIVI) will present Phase 2 trial data for its drug bezisterim at a US government-backed Long COVID workshop. The ADDRESS-LC study showed improvements in fatigue, post-exertional malaise, and cognitive function in severe cases. The trial, funded by a $13.13M grant, enrolled 200 adults with Long COVID. BioVie aims to identify patient subgroups for future Phase 3 trials.
3 min readSpaceX committed to a $40B lease for Nvidia chips. Xencor shares rose 20% on positive drug trial results. Surgery Partners surged 46% after a $5.7B acquisition deal. Tesla gained 6% following a Barclays upgrade. Verizon raised 2026 guidance after strong customer additions. Anthropic filed for IPO, with concerns raised about its valuation and spending. FTSE 100 gained 0.7%. Big Tech earnings and Fed decision are key focuses this week.
3 min readNew to The Street Show #777 features executives from Stewards Investment Capital, BioVie (NASDAQ:BIVI), FreeCast (NASDAQ:CAST), and American Fusion (OTCQB:AMFN). BioVie reports positive long COVID and Parkinson's trial results. FreeCast discusses its media monetization technology. American Fusion presents its fusion power technology. The show airs on Bloomberg Television and YouTube.
2 min readBioVie reported Phase 2 trial data showing bezisterim improved symptoms in Parkinson’s patients with higher platelet counts compared to placebo. Safety profiles were similar. The results were exploratory and require further Phase 3 trials for confirmation, according to the company.
1 min readBioVie Inc. (BIVI) reported Phase 2 trial results showing significant improvements in specific Long COVID patient subgroups, though the overall intent-to-treat population did not reach significance. The company plans further studies.
1 min readBioVie Inc reported that its Phase 2 ADDRESS-LC trial showed bezisterim significantly improved fatigue, post-exertional malaise, and cognitive symptoms in Long COVID patients with severe baseline conditions. The trial, presented at the American Neurological Association’s meeting, involved 203 patients and showed improvements in multiple measures. Bezisterim had a safety profile comparable to placebo. The study was funded by the U.S. Department of War.
2 min readBioVie Inc (BIVI, BIVIW) will present Phase 2 trial results for its drug bezisterim in Long COVID and Parkinson's disease at the American Neurological Association meeting. The trials showed improvements in inflammation, biomarkers, and symptoms. Bezisterim is designed to reduce inflammation and improve insulin sensitivity. The company also has ongoing trials in Alzheimer's disease.
2 min readBioVie (NASDAQ:BIVI) will host an investor webinar on September 23, 2026, to discuss Phase 2 results of its drug bezisterim for Long COVID. CEO Cuong Do will present findings showing potential across key symptoms and discuss implications for neurological disorders. The company believes positive results could support bezisterim's development for multiple CNS conditions.
2 min readBioVie Inc. (BIVI) reported Phase 2 trial results for Bezisterim, showing significant improvements in Long COVID patients with high baseline fatigue and cognitive impairment. The drug demonstrated advantages over placebo on 21 of 22 endpoints and had a similar safety profile to placebo. BioVie plans to advance to Phase 3 trials. BIVI stock is down 8.23% in pre-market trading.
2 min readBioVie's lead drug, Bezisterim, showed improvements in fatigue, malaise, and brain fog in a long COVID clinical trial, according to CEO Cuong Do. The NIH has not seen similar results in other long COVID studies. BioVie plans to analyze biomarker data and seek FDA feedback for a Phase 3 trial. The company is also advancing Bezisterim for Parkinson's disease.
2 min read
